Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2025

CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHexian LiQLQizhong LuZYZhengyu Yu

Discussion

Loading...

Member takes

Overview

Innovative CAR-T therapy demonstrates enhanced efficacy against AML by targeting CD123 and B7-H3, highlighting improved treatment options.

Key Points

  • The development of universal CAR-T cells aims to overcome treatment delays and antigen escape in acute myeloid leukemia.
  • Bispecific CAR-T cells show 82% to 87% transduction efficiency and enhanced cytotoxicity against AML cell lines.
  • In vitro and in vivo assessments indicate significant tumor inhibition and extended survival without major side effects.
  • This approach offers new strategies for tackling relapse issues in AML therapies, advancing current treatment methodologies.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/689e03efd61984b91e13d56bhttps://doi.org/10.1097/cm9.0000000000003588
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model2025
  2. 2Recent advances in universal chimeric antigen receptor T cell therapy2025 · 30 citations
  3. 3Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia2025 · 1 citations
  4. 4Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia2025
  5. 5CAR-T cells in hematologic disorders: acute myeloid leukemia - A systematic review of efficacy and safety2025 · 1 citations